Dasatinib salts
The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; hun |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Virag Attila Tothne Lauritz Maria Dr Dr. Marvanyos Ede Laszlo Varga Zoltan Dr. Pongo Laszlo Dr. Lukacs Gyula Dr. Dancso Andras Dr. Volk Balazs dr. Gregor Tamas Peregi Balazs |
| description | The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HU231013B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HU231013B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HU231013B13</originalsourceid><addsrcrecordid>eNrjZOB3SSxOLMnMy0xSKE7MKSnmYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxHqFGxoYGhsZOhsaEVQAACM8d-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Dasatinib salts</title><source>esp@cenet</source><creator>Virag Attila ; Tothne Lauritz Maria Dr ; Dr. Marvanyos Ede Laszlo ; Varga Zoltan ; Dr. Pongo Laszlo ; Dr. Lukacs Gyula ; Dr. Dancso Andras ; Dr. Volk Balazs ; dr. Gregor Tamas ; Peregi Balazs</creator><creatorcontrib>Virag Attila ; Tothne Lauritz Maria Dr ; Dr. Marvanyos Ede Laszlo ; Varga Zoltan ; Dr. Pongo Laszlo ; Dr. Lukacs Gyula ; Dr. Dancso Andras ; Dr. Volk Balazs ; dr. Gregor Tamas ; Peregi Balazs</creatorcontrib><description>The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.</description><language>eng ; hun</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191128&DB=EPODOC&CC=HU&NR=231013B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20191128&DB=EPODOC&CC=HU&NR=231013B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Virag Attila</creatorcontrib><creatorcontrib>Tothne Lauritz Maria Dr</creatorcontrib><creatorcontrib>Dr. Marvanyos Ede Laszlo</creatorcontrib><creatorcontrib>Varga Zoltan</creatorcontrib><creatorcontrib>Dr. Pongo Laszlo</creatorcontrib><creatorcontrib>Dr. Lukacs Gyula</creatorcontrib><creatorcontrib>Dr. Dancso Andras</creatorcontrib><creatorcontrib>Dr. Volk Balazs</creatorcontrib><creatorcontrib>dr. Gregor Tamas</creatorcontrib><creatorcontrib>Peregi Balazs</creatorcontrib><title>Dasatinib salts</title><description>The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZOB3SSxOLMnMy0xSKE7MKSnmYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxHqFGxoYGhsZOhsaEVQAACM8d-A</recordid><startdate>20191128</startdate><enddate>20191128</enddate><creator>Virag Attila</creator><creator>Tothne Lauritz Maria Dr</creator><creator>Dr. Marvanyos Ede Laszlo</creator><creator>Varga Zoltan</creator><creator>Dr. Pongo Laszlo</creator><creator>Dr. Lukacs Gyula</creator><creator>Dr. Dancso Andras</creator><creator>Dr. Volk Balazs</creator><creator>dr. Gregor Tamas</creator><creator>Peregi Balazs</creator><scope>EVB</scope></search><sort><creationdate>20191128</creationdate><title>Dasatinib salts</title><author>Virag Attila ; Tothne Lauritz Maria Dr ; Dr. Marvanyos Ede Laszlo ; Varga Zoltan ; Dr. Pongo Laszlo ; Dr. Lukacs Gyula ; Dr. Dancso Andras ; Dr. Volk Balazs ; dr. Gregor Tamas ; Peregi Balazs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HU231013B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; hun</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Virag Attila</creatorcontrib><creatorcontrib>Tothne Lauritz Maria Dr</creatorcontrib><creatorcontrib>Dr. Marvanyos Ede Laszlo</creatorcontrib><creatorcontrib>Varga Zoltan</creatorcontrib><creatorcontrib>Dr. Pongo Laszlo</creatorcontrib><creatorcontrib>Dr. Lukacs Gyula</creatorcontrib><creatorcontrib>Dr. Dancso Andras</creatorcontrib><creatorcontrib>Dr. Volk Balazs</creatorcontrib><creatorcontrib>dr. Gregor Tamas</creatorcontrib><creatorcontrib>Peregi Balazs</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Virag Attila</au><au>Tothne Lauritz Maria Dr</au><au>Dr. Marvanyos Ede Laszlo</au><au>Varga Zoltan</au><au>Dr. Pongo Laszlo</au><au>Dr. Lukacs Gyula</au><au>Dr. Dancso Andras</au><au>Dr. Volk Balazs</au><au>dr. Gregor Tamas</au><au>Peregi Balazs</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Dasatinib salts</title><date>2019-11-28</date><risdate>2019</risdate><abstract>The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; hun |
| recordid | cdi_epo_espacenet_HU231013B1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Dasatinib salts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-09T03%3A43%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Virag%20Attila&rft.date=2019-11-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHU231013B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |